Earnings Releases·Nov 5, 2026, 4:08 PM ET

Fulgent Genetics — Third Quarter 2026 Earnings Summary

Q3 2026 revenue reached $90.4 million, up 8% year-over-year from $84.1 million, while GAAP net loss narrowed to $13.2 million ($0.48/share) compared to a Non-GAAP net loss of $2.4 million ($0.09/share).
The company maintained full-year 2026 revenue guidance of $330.0–$340.0 million and improved its Non-GAAP loss outlook to $46.0–$50.0 million, reflecting a reduction in shares used for repurchases.
Cash position stands at $652.4 million, with $64.1 million utilized for stock repurchases year-to-date; future buybacks remain discretionary based on market conditions and economic factors.
Strategic momentum continues in the therapeutics pipeline with candidates FID-007 and FID-022, while AI integration in laboratory services has driven increased utilization and reliability following the resolution of prior billing system issues.